CytomX Therapeutics, a preclinical biotech developing tumor-activated cancer immunotherapies, raised $80 million by offering 6.7 million shares at $12, below the range of $14 to $16. CytomX Therapeutics plans to list on the Nasdaq under the symbol CTMX. CytomX Therapeutics initially filed confidentially on 7/24/2015. BofA Merrill Lynch, Jefferies and Cowen & Company acted as lead managers on the deal.
